The notion that onset of action of anti-The notion that onset of action of antidepressants takes several weeks is widely depressants takes several weeks is widely quoted in clinical guidelines (Anderson quoted in clinical guidelines (Anderson et et al al, 2000; National Institute for Clinical , 2000 ; National Institute for Clinical Excellence, 2004) and has formed the basis Excellence, 2004) and has formed the basis for considerable biological and pharma-for considerable biological and pharmacological research (Blier, 2003) . It is also cological research (Blier, 2003) . It is also a notion that has been thoroughly trans-a notion that has been thoroughly translated into clinical practice, where clinicians lated into clinical practice, where clinicians regularly tell patients that the anti-regularly tell patients that the antidepressant is likely to take 2 to 4 weeks to depressant is likely to take 2 to 4 weeks to start to work (Garfield start to work (Garfield et al et al, 2004) . Yet this , 2004 ). Yet this was not always the accepted view, and new was not always the accepted view, and new data suggest that this statement may be at data suggest that this statement may be at best misleading and at worst inaccurate. best misleading and at worst inaccurate.
THE DELAYED -ONSET THE DELAYED -ONSET HYPOTHESIS HYPOTHESIS
Conceptually, any drug that has a delayed Conceptually, any drug that has a delayed onset of action would be expected to show onset of action would be expected to show weak or negligible early efficacy but weak or negligible early efficacy but superior efficacy in the medium term. This superior efficacy in the medium term. This was examined in three antidepressant trials was examined in three antidepressant trials by a group from Columbia University, New by a group from Columbia University, New York; Quitkin York; Quitkin et al et al (1987) observed that (1987) observed that patients who achieved a sustained patients who achieved a sustained response tended to do so after several response tended to do so after several weeks' delay and, furthermore, those who weeks' delay and, furthermore, those who responded early often failed to continue to responded early often failed to continue to full remission. Yet in the past 15 years this full remission. Yet in the past 15 years this observation has been challenged, because a observation has been challenged, because a delayed response has not been replicated by delayed response has not been replicated by a number of independent groups (Dew a number of independent groups (Dew et et al al, 2001; Szegedi , 2001; Szegedi et al et al, 2003 Across all studies when outcome was defined as all studies when outcome was defined as a reduction in Hamilton Rating Scale for a reduction in Hamilton Rating Scale for Depression (HRSD) score, the authors Depression (HRSD) score, the authors showed that 23% of all differences between showed that 23% of all differences between drug and placebo groups were already drug and placebo groups were already apparent by week 1, and that 57% of apparent by week 1, and that 57% of possible differences had appeared by possible differences had appeared by week 2. Close inspection of responders in week 2. Close inspection of responders in both arms for the exact timing of their both arms for the exact timing of their improvement revealed no differences in improvement revealed no differences in the antidepressant the antidepressant v. v. placebo response rates placebo response rates during any week of treatment. Examination during any week of treatment. Examination of antidepressant improvement trajectories of antidepressant improvement trajectories in isolation was also valuable. It was found in isolation was also valuable. It was found that 60% of improvement that occurred that 60% of improvement that occurred across all trials with antidepressants took across all trials with antidepressants took place during the first 2 weeks. To look at place during the first 2 weeks. To look at this another way, in 80% of all trials the re-this another way, in 80% of all trials the response was greater in weeks 1 and 2 than it sponse was greater in weeks 1 and 2 than it was either in weeks 3 and 4 or in weeks 5 was either in weeks 3 and 4 or in weeks 5 and 6. On the basis of these data there seems and 6. On the basis of these data there seems to be little doubt that the largest to be little doubt that the largest improvement per unit time produced by anti-improvement per unit time produced by antidepressants occurs within the first 2 weeks of depressants occurs within the first 2 weeks of treatment. Yet we still do not know exactly treatment. Yet we still do not know exactly how early within this period antidepressants how early within this period antidepressants begin to work -that is, whether there is any begin to work -that is, whether there is any clinical clinical delay in the onset of action. delay in the onset of action.
MEASURING INITIAL ONSET MEASURING INITIAL ONSET OF THER APEUTIC ACTION OF THER APEUTIC ACTION
If we are to address initial onset of action -If we are to address initial onset of actionthat is, how long it takes a drug to that is, how long it takes a drug to begin begin to to work -we should not be satisfied with work -we should not be satisfied with studies that use standard definitions of studies that use standard definitions of response or remission, as neither of these response or remission, as neither of these accurately gauges first onset. Although accurately gauges first onset. Although some authors have defined onset of action some authors have defined onset of action as a 20% or 33% reduction in baseline as a 20% or 33% reduction in baseline severity scores, this approach conflates a severity scores, this approach conflates a true continuous variable (degree of suffer-true continuous variable (degree of suffering from depression) with a pseudo-linear ing from depression) with a pseudo-linear one (Parker one (Parker et al et al, 1997) . In addition, most , 1997). In addition, most clinical trials have not considered what clinical trials have not considered what proportion of improvement is due to proportion of improvement is due to natural (untreated) remission, because few natural (untreated) remission, because few studies leave cohorts completely untreated. studies leave cohorts completely untreated. Of the handful of studies that have used a Of the handful of studies that have used a waiting-list arm (mostly psychotherapy waiting-list arm (mostly psychotherapy studies), the typical rate of studies), the typical rate of spontaneous spontaneous remission of major depression (many stu-remission of major depression (many studies allow waiting-list patients to receive dies allow waiting-list patients to receive naturalistic treatment) is approximately naturalistic treatment) is approximately 10% per month, with a mean episode 10% per month, with a mean episode duration of 6 months (Posternak & Miller, duration of 6 months (Posternak & Miller, 2001) . This indicates that although both drug 2001). This indicates that although both drug and placebo arms offer substantial benefit, and placebo arms offer substantial benefit, some early remission would have occurred some early remission would have occurred without intervention, particularly if patients without intervention, particularly if patients were recruited at peak depression severity. were recruited at peak depression severity.
When trying to measure initial onset of When trying to measure initial onset of therapeutic action, a major methodological therapeutic action, a major methodological problem is finding an appropriate outcome problem is finding an appropriate outcome measure (Leon measure (Leon et al et al, 2001 ). An ideal , 2001). An ideal measure should have inherent linearity measure should have inherent linearity across a broad range of psychopathological across a broad range of psychopathological domains which translates into sensitivity to domains which translates into sensitivity to early change (Maier early change (Maier et al et al, 1988) . This , 1988 ). This hypothetical tool should also be applied hypothetical tool should also be applied early and frequently to increase temporal early and frequently to increase temporal resolution. The last point requires clarifica-resolution. The last point requires clarification. If there is even a possibility that anti-tion. If there is even a possibility that antidepressants begin to work depressants begin to work within within 2 weeks, 2 weeks, how could this be detected if the first how could this be detected if the first measurement takes place 2 weeks after measurement takes place 2 weeks after starting the drug? The same argument holds starting the drug? The same argument holds for 1 week or even 1 day. So although there for 1 week or even 1 day. So although there are definite disadvantages of measuring are definite disadvantages of measuring mood too often in a long-term study, if a mood too often in a long-term study, if a study is concerned with early onset of ac-study is concerned with early onset of action, measurement at 1 week (currently an tion, measurement at 1 week (currently an unusually prompt measurement) is cer-unusually prompt measurement) is certainly too late. This approach is not new. tainly too late. This approach is not new. Studies of the response to electroconvulsive Studies of the response to electroconvulsive therapy (ECT) often measure mood after therapy (ECT) often measure mood after each application two or even three times each application two or even three times weekly (Husain weekly (Husain et al et al, 2004) . As an aside, , 2004). As an aside, it would be interesting to see how much it would be interesting to see how much of the variance in rapidity of onset of action of the variance in rapidity of onset of action of ECT compared with pharmacotherapy of ECT compared with pharmacotherapy or psychotherapy is explained by differ-or psychotherapy is explained by differences in the frequency of assessment alone. ences in the frequency of assessment alone. Scales designed for regular daily mood rat-Scales designed for regular daily mood ratings have already appeared in other medical ings have already appeared in other medical specialties (Peters specialties (Peters et al et al, 2000) . Although , 2000) . Although these have often been in the form of simple these have often been in the form of simple visual analogue scales or mood diaries, one visual analogue scales or mood diaries, one group has used factor analysis to develop a group has used factor analysis to develop a daily mood scale for depression (Parker & daily mood scale for depression (Parker & Roy, 2003) . Daily or even twice daily Roy, 2003) . Daily or even twice daily manual or electronic mood diaries, manual or electronic mood diaries, although currently unfashionable, appear although currently unfashionable, appear to be easy to use and reliable (Sherliker & to be easy to use and reliable (Sherliker & Steptoe, 2000) . Subjective self-rating meth-Steptoe, 2000). Subjective self-rating methods are an equally important and powerful ods are an equally important and powerful method of assessing first onset, and provide method of assessing first onset, and provide different information to classical objective different information to classical objective scales when compared head to head scales when compared head to head (Moller (Moller et al et al, 1996 ). , 1996 .
LARGE-SCALE STUDIES LARGE-SCALE STUDIES
Some clinicians will remain unconvinced by Some clinicians will remain unconvinced by evidence extracted from multiple small evidence extracted from multiple small trials, albeit in the form of a meta-analysis trials, albeit in the form of a meta-analysis (Posternak & Zimmerman, 2005 , 2000) respectively. The results mirror those of the meta-analysis men-mirror those of the meta-analysis mentioned above. The Zurich group used daily tioned above. The Zurich group used daily depression ratings on the HRSD and Zung depression ratings on the HRSD and Zung Self-Rating Depression Scale. They found Self-Rating Depression Scale. They found that regardless of which antidepressant the that regardless of which antidepressant the patient was taking, there was a measurable patient was taking, there was a measurable early effect on day 1. By day 3, 20% of pa-early effect on day 1. By day 3, 20% of patients had shown some improvement, and tients had shown some improvement, and by day 7 50% had improved. Furthermore, by day 7 50% had improved. Furthermore, 90% of those who showed any response 90% of those who showed any response during the first 3 weeks went on to become during the first 3 weeks went on to become full responders. Drug-placebo differences full responders. Drug-placebo differences (where apparent) could be detected as early (where apparent) could be detected as early as day 5. In the third study, Parker's group as day 5. In the third study, Parker's group examined responders and non-responders examined responders and non-responders treated by 27 Australian and New Zealand treated by 27 Australian and New Zealand psychiatrists (Parker psychiatrists (Parker et al et al, 2000) . Patients , 2000) . Patients were requested to complete a self-report were requested to complete a self-report mood rating every third day. All patients mood rating every third day. All patients showed a decrease in depression (and anxiety) showed a decrease in depression (and anxiety) within the first 3 days, but with little further within the first 3 days, but with little further improvement in non-responders from days 4 improvement in non-responders from days 4 to 6. Again, early improvement within 1 week to 6. Again, early improvement within 1 week was a strong predictor of responder status. was a strong predictor of responder status.
Given these findings, it is pertinent to Given these findings, it is pertinent to ask why the view that antidepressants have ask why the view that antidepressants have a delayed onset of action is so commonly a delayed onset of action is so commonly held. There are two possibilities. The first held. There are two possibilities. The first is imprecision concerning the use of the is imprecision concerning the use of the term 'onset of action' when we really mean term 'onset of action' when we really mean 'time to substantial remission'. This is 'time to substantial remission'. This is understandable if we assume that patients understandable if we assume that patients want to know when they will feel much want to know when they will feel much improved rather than when they will begin improved rather than when they will begin to feel a little better. The second is a failure to feel a little better. The second is a failure to distinguish initial therapeutic benefit, to distinguish initial therapeutic benefit, which occurs within days of starting an which occurs within days of starting an antidepressant, from the concept of drug antidepressant, from the concept of drug v. v. placebo separation, which accrues more placebo separation, which accrues more slowly. In the Posternak and Zimmerman slowly. In the Posternak and Zimmerman meta-analysis of antidepressant meta-analysis of antidepressant v. v. placebo placebo responses, the active arm showed modest responses, the active arm showed modest but definite early efficacy, but this was but definite early efficacy, but this was difficult to separate from a significant difficult to separate from a significant placebo response until a week or more of placebo response until a week or more of cumulative benefit had occurred. These cumulative benefit had occurred. These limitations are amplified by relying on rela-limitations are amplified by relying on relatively blunt instruments applied infre-tively blunt instruments applied infrequently by observers. The implication for quently by observers. The implication for research is that sensitive daily measures research is that sensitive daily measures are required to elucidate whether these are required to elucidate whether these early patterns of response are dependent early patterns of response are dependent on biological correlates of antidepressant on biological correlates of antidepressant or placebo treatment (Mayberg or placebo treatment (Mayberg et al et al, 2002) . , 2002). The implication for clinical practice is that The implication for clinical practice is that current evidence suggests it would be more current evidence suggests it would be more accurate to say to patients that in 90% of accurate to say to patients that in 90% of cases substantial improvement occurs with-cases substantial improvement occurs within the first 2 weeks, but that benefit con-in the first 2 weeks, but that benefit continues to build up over several weeks. (In tinues to build up over several weeks. (In the meta-analysis by Posternak & Zimmer-the meta-analysis by Posternak & Zimmerman (2005) , 60 out of 66 study cohorts on man (2005), 60 out of 66 study cohorts on active medication showed a reduction in active medication showed a reduction in HRSD score of 50% or more within 2 weeks.) HRSD score of 50% or more within 2 weeks.) In those who have shown no response by 2 In those who have shown no response by 2 weeks there appears to be a law of dimin-weeks there appears to be a law of diminishing returns, which suggests that it may ishing returns, which suggests that it may be pertinent to re-examine another com-be pertinent to re-examine another commonly quoted recommendation -that an monly quoted recommendation -that an antidepressant trial must be at least 6 to 8 antidepressant trial must be at least 6 to 8 weeks before switching drugs. weeks before switching drugs.
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